World's Best Scientists 2026 revealed!
Daniel J. DeAngelo

Daniel J. DeAngelo

D-Index & Metrics

Medicine

D-Index
98
Citations
43079
World Ranking
8818
National Ranking
4543

Daniel J. DeAngelo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel J. DeAngelo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 600 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel J. DeAngelo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel J. DeAngelo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Daniel J. DeAngelo is affiliated with Harvard University in the United States and has a substantial body of work primarily in the field of medicine. Their research focuses on hematology, oncology, genetics, immunology, and public health, environmental and occupational health.

The scientist has contributed extensively to topics related to acute lymphoblastic leukemia research, acute myeloid leukemia research, chronic myeloid leukemia treatments, CAR-T cell therapy research, mast cells and histamine, chronic lymphocytic leukemia research, and eosinophilic disorders and syndromes.

DeAngelo's frequent co-authors include:

  • Richard M. Stone
  • Marlise R. Luskin
  • Jacqueline S. Garcia
  • Eric S. Winer
  • Martha Wadleigh

The scientist's work has been published predominantly in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia

Some of the recent publications include:

  • "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study", 2021, The Lancet
  • "Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology", 2020, Journal of the National Comprehensive Cancer Network
  • "Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis", 2023, NEJM Evidence
  • "Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology", 2021, Journal of the National Comprehensive Cancer Network
  • "Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms", 2021, Cell stem cell

Their academic contributions highlight a focus on clinical practices, disease risk predictions, and cellular-level research on blood cancers and related disorders.

Best Publications

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

    Yana Pikman;Benjamin H Lee;Thomas Mercher;Elizabeth McDowell

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

    Pasha Sarraf;Elisabetta Mueller;Daniel Jones;Frederick J. King

  • Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

    Hagop M. Kantarjian;Daniel J. DeAngelo;Matthias Stelljes;Giovanni Martinelli

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

    John Koreth;Richard Schlenk;Kenneth J. Kopecky;Sumihisa Honda

  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

    R. Coleman Lindsley;Brenton G. Mar;Emanuele Mazzola;Peter V. Grauman

  • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    Richard M. Stone;Daniel J. DeAngelo;Virginia Klimek;Ilene Galinsky

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

    Rongqing Pan;Leah J. Hogdal;Juliana M. Benito;Donna Bucci

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    Bijal D Shah;Armin Ghobadi;Olalekan O Oluwole;Aaron C Logan

  • Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Jorge E. Cortes;Dong Wook Kim;Javier Pinilla-Ibarz;Philipp D. le Coutre

  • Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

    Martha Wadleigh;Paul G. Richardson;David Zahrieh;Stephanie J. Lee

  • Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

    Akinori Yoda;Yuka Yoda;Sabina Chiaretti;Michal Bar-Natan

  • Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

    Ofir Wolach;Ofir Wolach;Ofir Wolach;Rob S. Sellar;Rob S. Sellar;Rob S. Sellar;Kimberly Martinod;Deya Cherpokova

  • Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

    Edwin P Alyea;Edwin P Alyea;Haesook T Kim;Haesook T Kim;Vincent T Ho;Vincent T Ho;Corey Cutler;Corey Cutler

  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

    Eytan M. Stein;Courtney Denton Dinardo;Daniel Aaron Pollyea;Amir Tahmasb Fathi

Frequent Co-Authors

Richard Stone
Richard Stone Harvard University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
David P. Steensma
David P. Steensma Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michael W. Deininger
Michael W. Deininger University of Utah
Susan O'Brien
Susan O'Brien University of California, Irvine
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Robert J. Soiffer
Robert J. Soiffer Harvard University
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens doors to a variety of related pathways and online degrees. If you are a registered nurse seeking to boost your credentials or increase earning potential, pursuing one of the rn to bsn cheapest programs is an affordable option. These programs are flexible and allow you to keep working as you study.

For those with a non-nursing background but interested in nursing, direct entry msn online pathways offer a fast track into advanced nursing roles without needing a traditional BSN. Admission requirements can vary, but some students prioritize finding easy nursing programs to get into to accelerate their entry into the healthcare workforce.

Not all healthcare careers require a medical degree. Medical billing and coding is a growing field with online training options—and you may be wondering, can you get financial aid for medical billing and coding? Financial assistance is often available, making it easier for students to enter this essential healthcare support career.

Best Scientists Citing Daniel J. DeAngelo

Trending Scientists

Recently Published Articles